{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:21:08Z","timestamp":1771734068515,"version":"3.50.1"},"reference-count":76,"publisher":"Oncology Nursing Society (ONS)","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2011,8,1]]},"DOI":"10.1188\/11.s1.cjon.9-23","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T21:42:03Z","timestamp":1312494123000},"page":"9-23","source":"Crossref","is-referenced-by-count":34,"title":["Maintaining Bone Health in Patients With Multiple Myeloma"],"prefix":"10.1188","volume":"15","author":[{"given":"Teresa S.","family":"Miceli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Colson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth M.","family":"Faiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kena","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Tariman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2011,8,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1185\/03007990902801147","article-title":"Bone health in diabetes: Considerations for clinical management","volume":"25","author":"S. Adami","year":"2009","journal-title":"Current Medical Research and Opinion"},{"key":"2","doi-asserted-by":"crossref","DOI":"10.1093\/ajcn\/88.2.545S","article-title":"African Americans, 25-hydroxyvitamin D, and osteoporosis: A paradox","volume":"88","author":"J. Aloia","year":"2008","journal-title":"American Journal of Clinical Nutrition"},{"key":"3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1148\/radiol.2311020452","article-title":"Multiple myeloma: Clinical review and diagnostic imaging","volume":"231","author":"E. Angtuaco","year":"2004","journal-title":"Radiology"},{"key":"4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00590-002-0013-x","article-title":"Intramedullary spread of tumour cells during IM nailing: A histological diagnosis","volume":"12","author":"N. Awan","year":"2002","journal-title":"European Journal of Orthopaedic Surgery and Traumatology"},{"key":"5","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"T. Bartel","year":"2009","journal-title":"Blood"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70008-0","article-title":"Balloon kyphoplasty versus nonsurgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: A multicentre, randomized controlled trial","author":"J. Berenson","year":"2011","journal-title":"Lancet Oncology"},{"key":"7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.4161\/cbt.5.9.3307","article-title":"Bone complications in multiple myeloma","volume":"5","author":"J. Berenson","year":"2006","journal-title":"Cancer Biology and Therapy"},{"key":"8","first-page":"381","article-title":"Managing the adverse effects of radiation therapy","volume":"82","author":"F. Berkey","year":"2010","journal-title":"American Family Physician"},{"issue":"3-5","key":"9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jsbmb.2006.12.016","article-title":"The 25-hydroxyvitamin D threshold for better health","volume":"103","author":"H. Bischoff-Ferrari","year":"2007","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10","unstructured":"Bolzoni, M., Abeltino, M., Storti, P., Bonomini, S., Agnelli, L., Todoerti, K., \u2026 Giuliani, N. (2010). The immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL\/OPG ratio in myleoma microenvironment targeting the expression of adhesion molecules [Abstract 448]. Retrieved from <a target=\"_blank\" href='http:\/\/ash.confex.com\/ash\/2010\/webprogram\/Paper29811.html'>http:\/\/ash.confex.com\/ash\/2010\/webprogram\/Paper29811.html<\/a>"},{"key":"11","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors, and bone-remodeling markers in multiple myeloma","volume":"22","author":"I. Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jamcollsurg.2004.10.007","article-title":"Part 1: Surgical palliation of advanced illness\u2014What's new, what's helpful","volume":"200","author":"B. Cady","year":"2005","journal-title":"Journal of the American College of Surgeons"},{"key":"13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3816\/CLM.2008.n.013","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Definition and management of the risk related to zoledronic acid","volume":"8","author":"A. Cafro","year":"2008","journal-title":"Clinical Lymphoma and Myeloma"},{"issue":"11","key":"14","doi-asserted-by":"crossref","DOI":"10.1093\/jn\/137.11.2507S","article-title":"Diet, nutrition, and bone health","volume":"137","author":"K. Cashman","year":"2007","journal-title":"Journal of Nutrition"},{"key":"15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2337\/diaclin.20.3.153","article-title":"Osteoporosis and diabetes","volume":"20","author":"D. Chau","year":"2002","journal-title":"Clinical Diabetes"},{"key":"16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","article-title":"Management of bone metastases","volume":"5","author":"R. Coleman","year":"2000","journal-title":"Oncologist"},{"issue":"3","key":"17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology, and treatment strategies","volume":"27","author":"R. Coleman","year":"2001","journal-title":"Cancer Treatment Reviews"},{"issue":"20","key":"18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"R. Coleman","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"19","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2009-06-224196","article-title":"A new pet for myeloma","volume":"114","author":"M. Dimopoulos","year":"2009","journal-title":"Blood"},{"key":"20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509) 36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"B. Durie","year":"1975","journal-title":"Cancer"},{"key":"21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","article-title":"The role of anatomic and functional staging in myeloma: Description of Durie\/Salmon PLUS staging system","volume":"42","author":"B. Durie","year":"2006","journal-title":"European Journal of Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4065\/82.4.516","article-title":"Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement","volume":"82","author":"B. Durie","year":"2007","journal-title":"Mayo Clinic Proceedings"},{"key":"23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1359\/jbmr.1999.14.3.342","article-title":"Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation","volume":"14","author":"P. Ebeling","year":"1999","journal-title":"Journal of Bone Mineral Research"},{"key":"24","first-page":"300","article-title":"Myeloma and bone disease: The dangerous tango","volume":"4","author":"J. Epstein","year":"2006","journal-title":"Clinical Advances in Hematolology and Oncology"},{"key":"25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.beha.2007.08.003","article-title":"Pathophysiology of myeloma bone disease","volume":"20","author":"F. Esteve","year":"2007","journal-title":"Best Practice in Research and Clinical Haematology"},{"key":"26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ciia.2006.1.1.11","article-title":"Dietary approaches that delay age-related diseases","volume":"1","author":"A. Everitt","year":"2006","journal-title":"Clinical Interventions in Aging"},{"issue":"3","key":"27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1188\/08.CJON.S1.53-62","article-title":"Consensus statement for the management of steroid-associated side effects in patients with multiple myeloma","volume":"12","author":"B. Faiman","year":"2008","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"4","key":"28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1188\/11.CJON.S1.66-76","article-title":"Renal complications in multiple myeloma and related disorders: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board","volume":"15","author":"B. Faiman","year":"2011","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1188\/08.ONF.709-713","article-title":"Bisphosphonate therapy for metastatic bone disease: The pivotal role of nurses in patient education","volume":"35","author":"M. Fitch","year":"2008","journal-title":"Oncology Nursing Forum"},{"key":"30","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1182\/blood-2008-07-171389","article-title":"Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors","volume":"113","author":"E. Golden","year":"2009","journal-title":"Blood"},{"key":"31","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"P. Greipp","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"32","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","article-title":"Bone loss and fracture risk associated with cancer therapy","volume":"11","author":"T. Guise","year":"2006","journal-title":"Oncologist"},{"key":"33","first-page":"101","article-title":"Radiotherapy in the management of plasma cell tumors","volume":"14","author":"K. Hu","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S8756-3282(99)00265-3","article-title":"The short-term changes of bone mineral metabolism following bone marrow transplantation","volume":"26","author":"M. Kang","year":"2000","journal-title":"Bone"},{"issue":"12","key":"35","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1002\/1097-0142(20000615)88:12+<3022::AID-CNCR19>3.0.CO;2-R","article-title":"Bisphosphonates in multiple myeloma","volume":"88","author":"J. Kanis","year":"2000","journal-title":"Cancer"},{"key":"36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/sj.bmt.1704618","article-title":"Bone metabolism in patients more than five years after bone marrow transplantation","volume":"34","author":"K. Kerschan-Schindl","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"37","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1617::AID-CNCR27>3.0.CO;2-#","article-title":"Endocrine function and bone metabolism 5 years after autologous bone marrow\/blood-derived progenitor cell transplantation","volume":"79","author":"U. Kielholz","year":"1997","journal-title":"Cancer"},{"key":"38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: A report of the International Myeloma Working Group","volume":"121","author":"R. Kyle","year":"2003","journal-title":"British Journal of Haematology"},{"key":"39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1,027 patients with newly diagnosed multiple myeloma","volume":"78","author":"R. Kyle","year":"2003","journal-title":"Mayo Clinic Proceedings"},{"key":"40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.beha.2007.08.001","article-title":"Epidemiology of the plasma-cell disorders","volume":"20","author":"R. Kyle","year":"2007","journal-title":"Best Practice and Research Clinical Hematology"},{"key":"41","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/archinte.145.8.1451","article-title":"Computed tomography in diagnosis and management of multiple myeloma and its variants","volume":"145","author":"R. Kyle","year":"1985","journal-title":"Archives of Internal Medicine"},{"key":"42","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"R. Kyle","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1210\/jc.87.1.329","article-title":"The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells","volume":"87","author":"W. Lee","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"44","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3346\/jkms.2002.17.6.749","article-title":"The skeletal site-differential changes in bone mineral density following bone marrow transplantation: Three-year prospective study","volume":"17","author":"W. Lee","year":"2002","journal-title":"Journal of Korean Medical Sciences"},{"issue":"6","key":"45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00000446-200506000-00024","article-title":"Complications of chronic kidney disease","volume":"105","author":"V. Legg","year":"2005","journal-title":"American Journal of Nursing"},{"key":"46","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJM199610103351507","article-title":"Pharmacologic treatment of cancer pain","volume":"335","author":"M. Levy","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"47","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.beha.2007.10.001","article-title":"Supportive care in multiple myeloma","volume":"20","author":"H. Ludwig","year":"2007","journal-title":"Best Practice and Research in Clinical Haematology"},{"key":"48","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1046\/j.1365-2141.1999.01244.x","article-title":"Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma","volume":"104","author":"X. Mariette","year":"1999","journal-title":"British Journal of Haematology"},{"key":"49","doi-asserted-by":"publisher","first-page":"662","DOI":"10.4065\/81.5.662","article-title":"Diagnosis, screening, prevention, and treatment of osteoporosis","volume":"81","author":"K. Mauck","year":"2006","journal-title":"Mayo Clinic Proceedings"},{"key":"50","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1188\/03.CJON.403-408","article-title":"Advances in supportive care of patients with cancer and bone metastasis: Nursing implications of zoledronic acid","volume":"7","author":"C. Maxwell","year":"2003","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: A population-based study","volume":"20","author":"L. Melton III","year":"2005","journal-title":"Journal of Bone and Minereral Research"},{"key":"52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-007-0449-2","article-title":"Depression and osteoporosis: Epidemiology and potential mediating pathways","volume":"9","author":"B. Mezuk","year":"2008","journal-title":"Osteoporosis International"},{"key":"53","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/gerona\/63.12.1410","article-title":"Depression, antidepressants, and bone mineral density in a population-based cohort","volume":"63","author":"B. Mezuk","year":"2008","journal-title":"Journal of Gerontology A, Biologic Science and Medical Science"},{"key":"54","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"V. Montefusco","year":"2008","journal-title":"Leukemia and Lymphoma"},{"key":"55","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodonic acid in multiple myeloma (MRC Myeloma IX): A randomized controlled trial","volume":"376","author":"G. Morgan","year":"2010","journal-title":"Lancet"},{"key":"56","unstructured":"National Comprehensive Cancer Network. (2010). <i>Clinical Practice Guidelines in Oncology\u2122: Multiple myeloma<\/i> [v.3.2010]. Retrieved from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp'>http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp<\/a>"},{"key":"57","unstructured":"National Osteoporosis Foundation. (2010). Fast facts on osteoporosis, 2010. Retrieved from <a target=\"_blank\" href='http:\/\/www.nof.org\/osteoporosis\/diseasefacts.htm#top'>http:\/\/www.nof.org\/osteoporosis\/diseasefacts.htm#top<\/a>"},{"key":"58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib, suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"A. Pennisi","year":"2009","journal-title":"American Journal of Hematology"},{"issue":"4","key":"59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1188\/11.S1.CJON.41-52","article-title":"Mobility and safety in the multiple myeloma survivor: Survivorship care plan of the IMF Nurse Leadership Board","volume":"15","author":"S. Rome","year":"2011","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"60","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"G. Roodman","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"61","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/asheducation-2008.1.313","article-title":"Skeletal imaging and management of bone disease","author":"G. Roodman","year":"2008","journal-title":"Hematology: American Society of Hematology Education Program"},{"key":"62","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1634\/theoncologist.2009-0003","article-title":"Myeloma bone disease: Recent advances in biology, diagnosis, and treatment","volume":"14","author":"O. Sezer","year":"2009","journal-title":"Oncologist"},{"key":"63","unstructured":"Steinberg, J.A., Shen, J., Sanchez, E., Chen, H., Li, Z.W., Hilger, J., & Berenson, J.R., (2009). Alpha lipoic acid (ALA) inhibits the antimyeloma effects of bortezomib [Abstract 3832]. Retrieved from <a target=\"_blank\" href='http:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper19795.html'>http:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper19795.html<\/a>"},{"key":"64","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1359\/jbmr.070903","article-title":"Calcifications in the abdominal aorta predict fractures in men: MINOS study","volume":"23","author":"P. Szulc","year":"2008","journal-title":"Journal of Bone and Mineral Research"},{"key":"65","first-page":"1513","volume-title":"Cancer nursing principles and practice","author":"J. Tariman","year":"2011"},{"key":"66","doi-asserted-by":"publisher","DOI":"10.1188\/05.ONF.E127-E138","article-title":"The changing treatment paradigm in patients with newly diagnosed multiple myeloma: Implications for nursing [Online exclusive]","volume":"32","author":"J. Tariman","year":"2005","journal-title":"Oncology Nursing Forum"},{"key":"67","article-title":"Effect of lenalidomide-based regimens on bone remodeling in patients with relapsed\/refractory multiple myeloma [Abstract 0192]","author":"E. Terpos","year":"2008"},{"key":"68","unstructured":"Terpos, E., Christoulas, D., Migkou, M., Gavriatopoulou, M., Papatheodorou, A., Eleutherakis-Papaiakouvou, E., \u2026 Dimopoulos, M.A. (2009). Consolidation therapy with bortezomib, thalidomide, and dexamethasone (VTD) regimen after ASCT in myleoma patients who do not receive bisphosphonates reduces bone resorption and RANKL\/OPG ratio but seems to have no effect on bone formation and angiogenesis [Abstract: 3863]. Retrived from <a target=\"_blank\" href='http:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper18577.html'>http:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper18577.html<\/a>"},{"key":"69","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: Pathophysiology and management","volume":"16","author":"E. Terpos","year":"2005","journal-title":"Annals of Oncology"},{"key":"70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0001-2998(97)80044-X","article-title":"Oncologic imaging: Interactions of nuclear medicine with CT and MRI using the bone scan as a model","volume":"27","author":"E. Tryciecky","year":"1997","journal-title":"Seminars in Nuclear Medicine"},{"key":"71","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"K. Vahtsevanos","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/asheducation-2005.1.373","article-title":"Solitary bone and extramedullary plasmacy-toma","volume":"1","author":"D. Weber","year":"2005","journal-title":"Hematology"},{"key":"73","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4140\/TCP.n.2009.100","article-title":"Spontaneous fracture: Multiple causes","volume":"24","author":"J. Wick","year":"2009","journal-title":"Consultant Pharmacologist"},{"key":"74","unstructured":"World Health Organization. (2009). WHO's pain ladder. Retrieved from <a target=\"_blank\" href='http:\/\/www.who.int\/cancer\/palliative\/painladder\/en'>http:\/\/www.who.int\/cancer\/palliative\/painladder\/en<\/a>"},{"issue":"20","key":"75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0681","article-title":"Treatment for myeloma bone disease","volume":"12","author":"H. Yeh","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/1078-0432.CCR-05-0503","article-title":"Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells","volume":"12","author":"W. Zou","year":"2006","journal-title":"Clinical Cancer Research"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/674170092776541X.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:48:26Z","timestamp":1763754506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/15\/4\/supplement-august-2011-myeloma-research\/maintaining-bone-health"}},"subtitle":["Survivorship Care Plan of the International Myeloma Foundation Nurse Leadership Board"],"short-title":[],"issued":{"date-parts":[[2011,8,1]]},"references-count":76,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2011,8,1]]}},"alternative-id":["674170092776541X"],"URL":"https:\/\/doi.org\/10.1188\/11.s1.cjon.9-23","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,1]]}}}